Norris Medicines Ltd. significantly lags behind its peers in key financial metrics, exhibiting no growth, profitability, or valuation appeal. Companies like Sun Pharma and Cipla stand out as leaders in profitability and growth, while others like Divi's Laboratories and Torrent Pharmaceuticals show relatively high valuations despite their solid performance. The sector indicates strong players, but Norris Medicines appears financially distressed.

• • Norris Medicines Ltd. shows zero revenue growth and negative earnings metrics.
• • Sun Pharmaceutical Industries leads in profitability with an ROE of 16.13% and high growth.
• • Cipla Ltd. presents a solid combination of profitability and value metrics, making it a recommended buy.
• • Divi's Laboratories and Torrent Pharmaceuticals are at risk of being overvalued despite decent performance.